Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and validation of a machine-learning ALS survival model lacking vital capacity (VC-Free) for use in clinical trials during the COVID-19 pandemic.
Beaulieu D, Berry JD, Paganoni S, Glass JD, Fournier C, Cuerdo J, Schactman M, Ennist DL. Beaulieu D, et al. Among authors: paganoni s. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(sup1):22-32. doi: 10.1080/21678421.2021.1924207. Amyotroph Lateral Scler Frontotemporal Degener. 2021. PMID: 34348539 Free article.
Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS).
Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, Cudkowicz M, Atassi N. Paganoni S, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):453-6. doi: 10.3109/21678421.2014.903974. Epub 2014 Jul 1. Amyotroph Lateral Scler Frontotemporal Degener. 2014. PMID: 24981792 Free PMC article.
Serum urate at trial entry and ALS progression in EMPOWER.
O'Reilly ÉJ, Liu D, Johns DR, Cudkowicz ME, Paganoni S, Schwarzschild MA, Leitner M, Ascherio A. O'Reilly ÉJ, et al. Among authors: paganoni s. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):120-125. doi: 10.1080/21678421.2016.1214733. Epub 2016 Sep 28. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 27677562 Free PMC article. Clinical Trial.
Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability.
Berry JD, Paganoni S, Atassi N, Macklin EA, Goyal N, Rivner M, Simpson E, Appel S, Grasso DL, Mejia NI, Mateen F, Gill A, Vieira F, Tassinari V, Perrin S. Berry JD, et al. Among authors: paganoni s. Muscle Nerve. 2017 Dec;56(6):1077-1084. doi: 10.1002/mus.25733. Epub 2017 Aug 29. Muscle Nerve. 2017. PMID: 28662296 Free PMC article. Clinical Trial.
Experience with telemedicine in a multi-disciplinary ALS clinic.
Van De Rijn M, Paganoni S, Levine-Weinberg M, Campbell K, Swartz Ellrodt A, Estrada J, Cohen AB, Schwamm LH, Berry JD. Van De Rijn M, et al. Among authors: paganoni s. Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):143-148. doi: 10.1080/21678421.2017.1392577. Epub 2017 Dec 18. Amyotroph Lateral Scler Frontotemporal Degener. 2018. PMID: 29250986
Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis.
Bjornevik K, O'Reilly ÉJ, Berry JD, Clish CB, Jeanfavre S, Kato I, Kolonel LN, Le Marchand L, McCullough ML, Paganoni S, Schwarzschild MA, Talbott EO, Wallace RB, Zhang Z, Manson JE, Ascherio A. Bjornevik K, et al. Among authors: paganoni s. Neurology. 2019 Apr 30;92(18):e2081-e2088. doi: 10.1212/WNL.0000000000006669. Epub 2018 Nov 14. Neurology. 2019. PMID: 30429276 Free PMC article.
161 results